TISIDB

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted.
Domain	PF00048 Small cytokines (intecrine/chemokine)
Function	Inhibits hemopoiesis and stimulates chemotaxis. Chemotactic in vitro for thymocytes and activated T-cells, but not for B-cells, macrophages, or neutrophils. Shows preferential activity towards naive T-cells. May play a role in mediating homing of lymphocytes to secondary lymphoid organs. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4.

> Gene Ontology [ TOP ]
Biological Process	GO:0001767 establishment of lymphocyte polarity GO:0001768 establishment of T cell polarity GO:0001771 immunological synapse formation GO:0001952 regulation of cell-matrix adhesion GO:0001954 positive regulation of cell-matrix adhesion GO:0002407 dendritic cell chemotaxis GO:0002408 myeloid dendritic cell chemotaxis GO:0002468 dendritic cell antigen processing and presentation GO:0002548 monocyte chemotaxis GO:0002577 regulation of antigen processing and presentation GO:0002579 positive regulation of antigen processing and presentation GO:0002604 regulation of dendritic cell antigen processing and presentation GO:0002606 positive regulation of dendritic cell antigen processing and presentation GO:0002683 negative regulation of immune system process GO:0002685 regulation of leukocyte migration GO:0002686 negative regulation of leukocyte migration GO:0002687 positive regulation of leukocyte migration GO:0002688 regulation of leukocyte chemotaxis GO:0002690 positive regulation of leukocyte chemotaxis GO:0002691 regulation of cellular extravasation GO:0002692 negative regulation of cellular extravasation GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0006644 phospholipid metabolic process GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006898 receptor-mediated endocytosis GO:0007015 actin filament organization GO:0007159 leukocyte cell-cell adhesion GO:0007160 cell-matrix adhesion GO:0007162 negative regulation of cell adhesion GO:0007163 establishment or maintenance of cell polarity GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007254 JNK cascade GO:0008037 cell recognition GO:0008064 regulation of actin polymerization or depolymerization GO:0008154 actin polymerization or depolymerization GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0009988 cell-cell recognition GO:0010559 regulation of glycoprotein biosynthetic process GO:0010560 positive regulation of glycoprotein biosynthetic process GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0019216 regulation of lipid metabolic process GO:0019882 antigen processing and presentation GO:0021700 developmental maturation GO:0022407 regulation of cell-cell adhesion GO:0022408 negative regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030010 establishment of cell polarity GO:0030031 cell projection assembly GO:0030041 actin filament polymerization GO:0030100 regulation of endocytosis GO:0030335 positive regulation of cell migration GO:0030336 negative regulation of cell migration GO:0030593 neutrophil chemotaxis GO:0030595 leukocyte chemotaxis GO:0030832 regulation of actin filament length GO:0030833 regulation of actin filament polymerization GO:0030838 positive regulation of actin filament polymerization GO:0031098 stress-activated protein kinase signaling cascade GO:0031268 pseudopodium organization GO:0031269 pseudopodium assembly GO:0031272 regulation of pseudopodium assembly GO:0031274 positive regulation of pseudopodium assembly GO:0031294 lymphocyte costimulation GO:0031295 T cell costimulation GO:0031334 positive regulation of protein complex assembly GO:0031345 negative regulation of cell projection organization GO:0031346 positive regulation of cell projection organization GO:0031529 ruffle organization GO:0031589 cell-substrate adhesion GO:0032103 positive regulation of response to external stimulus GO:0032271 regulation of protein polymerization GO:0032273 positive regulation of protein polymerization GO:0032535 regulation of cellular component size GO:0032844 regulation of homeostatic process GO:0032845 negative regulation of homeostatic process GO:0032872 regulation of stress-activated MAPK cascade GO:0032874 positive regulation of stress-activated MAPK cascade GO:0032956 regulation of actin cytoskeleton organization GO:0032970 regulation of actin filament-based process GO:0033627 cell adhesion mediated by integrin GO:0033628 regulation of cell adhesion mediated by integrin GO:0033630 positive regulation of cell adhesion mediated by integrin GO:0033674 positive regulation of kinase activity GO:0034341 response to interferon-gamma GO:0034612 response to tumor necrosis factor GO:0034694 response to prostaglandin GO:0034695 response to prostaglandin E GO:0035759 mesangial cell-matrix adhesion GO:0036336 dendritic cell migration GO:0040013 negative regulation of locomotion GO:0040017 positive regulation of locomotion GO:0042110 T cell activation GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043254 regulation of protein complex assembly GO:0043410 positive regulation of MAPK cascade GO:0043491 protein kinase B signaling GO:0043550 regulation of lipid kinase activity GO:0043551 regulation of phosphatidylinositol 3-kinase activity GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity GO:0044089 positive regulation of cellular component biogenesis GO:0045123 cellular extravasation GO:0045785 positive regulation of cell adhesion GO:0045807 positive regulation of endocytosis GO:0045834 positive regulation of lipid metabolic process GO:0045860 positive regulation of protein kinase activity GO:0046328 regulation of JNK cascade GO:0046330 positive regulation of JNK cascade GO:0046847 filopodium assembly GO:0048247 lymphocyte chemotaxis GO:0048259 regulation of receptor-mediated endocytosis GO:0048260 positive regulation of receptor-mediated endocytosis GO:0048469 cell maturation GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0050900 leukocyte migration GO:0050901 leukocyte tethering or rolling GO:0050920 regulation of chemotaxis GO:0050921 positive regulation of chemotaxis GO:0051208 sequestering of calcium ion GO:0051209 release of sequestered calcium ion into cytosol GO:0051235 maintenance of location GO:0051238 sequestering of metal ion GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051258 protein polymerization GO:0051271 negative regulation of cellular component movement GO:0051272 positive regulation of cellular component movement GO:0051282 regulation of sequestering of calcium ion GO:0051283 negative regulation of sequestering of calcium ion GO:0051403 stress-activated MAPK cascade GO:0051480 regulation of cytosolic calcium ion concentration GO:0051489 regulation of filopodium assembly GO:0051491 positive regulation of filopodium assembly GO:0051493 regulation of cytoskeleton organization GO:0051495 positive regulation of cytoskeleton organization GO:0051896 regulation of protein kinase B signaling GO:0051897 positive regulation of protein kinase B signaling GO:0055074 calcium ion homeostasis GO:0060326 cell chemotaxis GO:0060401 cytosolic calcium ion transport GO:0060402 calcium ion transport into cytosol GO:0060491 regulation of cell projection assembly GO:0060627 regulation of vesicle-mediated transport GO:0061756 leukocyte adhesion to vascular endothelial cell GO:0070098 chemokine-mediated signaling pathway GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070304 positive regulation of stress-activated protein kinase signaling cascade GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070374 positive regulation of ERK1 and ERK2 cascade GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070509 calcium ion import GO:0070555 response to interleukin-1 GO:0070588 calcium ion transmembrane transport GO:0070838 divalent metal ion transport GO:0071346 cellular response to interferon-gamma GO:0071347 cellular response to interleukin-1 GO:0071356 cellular response to tumor necrosis factor GO:0071593 lymphocyte aggregation GO:0071621 granulocyte chemotaxis GO:0071622 regulation of granulocyte chemotaxis GO:0071624 positive regulation of granulocyte chemotaxis GO:0071674 mononuclear cell migration GO:0071887 leukocyte apoptotic process GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0072676 lymphocyte migration GO:0072678 T cell migration GO:0090022 regulation of neutrophil chemotaxis GO:0090023 positive regulation of neutrophil chemotaxis GO:0090066 regulation of anatomical structure size GO:0090218 positive regulation of lipid kinase activity GO:0090630 activation of GTPase activity GO:0097026 dendritic cell dendrite assembly GO:0097529 myeloid leukocyte migration GO:0097530 granulocyte migration GO:0097553 calcium ion transmembrane import into cytosol GO:1901654 response to ketone GO:1902622 regulation of neutrophil migration GO:1902624 positive regulation of neutrophil migration GO:1902656 calcium ion import into cytosol GO:1903018 regulation of glycoprotein metabolic process GO:1903020 positive regulation of glycoprotein metabolic process GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903038 negative regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903236 regulation of leukocyte tethering or rolling GO:1903237 negative regulation of leukocyte tethering or rolling GO:1903725 regulation of phospholipid metabolic process GO:1903727 positive regulation of phospholipid metabolic process GO:1904994 regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1990266 neutrophil migration GO:2000021 regulation of ion homeostasis GO:2000106 regulation of leukocyte apoptotic process GO:2000107 negative regulation of leukocyte apoptotic process GO:2000146 negative regulation of cell motility GO:2000147 positive regulation of cell motility GO:2000401 regulation of lymphocyte migration GO:2000403 positive regulation of lymphocyte migration GO:2000404 regulation of T cell migration GO:2000406 positive regulation of T cell migration GO:2000508 regulation of dendritic cell chemotaxis GO:2000510 positive regulation of dendritic cell chemotaxis GO:2000527 regulation of myeloid dendritic cell chemotaxis GO:2000529 positive regulation of myeloid dendritic cell chemotaxis GO:2000547 regulation of dendritic cell dendrite assembly GO:2000548 negative regulation of dendritic cell dendrite assembly
Molecular Function	GO:0001664 G-protein coupled receptor binding GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0008009 chemokine activity GO:0031732 CCR7 chemokine receptor binding GO:0042379 chemokine receptor binding GO:0048020 CCR chemokine receptor binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04062 Chemokine signaling pathway hsa04064 NF-kappa B signaling pathway
Reactome	R-HSA-380108: Chemokine receptors bind chemokines R-HSA-373076: Class A/1 (Rhodopsin-like receptors) R-HSA-418594: G alpha (i) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-500792: GPCR ligand binding R-HSA-375276: Peptide ligand-binding receptors R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CCL21 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CCL21 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
16540672	Lung Carcinoma	Promote immunity (infiltration)	A single intratracheal administration of CCL21 gene-modified dendritic cells (DC-AdCCL21) led to a marked reduction in tumor burden with extensive mononuclear cell infiltration of the tumors. The reduction in tumor burden was accompanied by the enhanced elaboration of type 1 cytokines [IFN-gamma, interleukin (IL)-12, and granulocyte macrophage colony-stimulating factor] and antiangiogenic chemokines (CXCL9 and CXCL10) but a concomitant decrease in the immunosuppressive molecules (IL-10, transforming growth factor-beta, prostaglandin E(2)) in the tumor microenvironment. The DC-AdCCL21 therapy group revealed a significantly greater frequency of tumor-specific T cells releasing IFN-gamma compared with the controls.
24304581	Hepatocellular Carcinoma	Promote immunity	In this study, we proposed the combination therapy of intratumoral co-administration of SLC and anti-CD25 monoclonal antibodies (mAbs). Our experiments showed the combination therapy significantly decreased the frequency of Tregs, and increased CD8+ T cells and CD4+ T cells at tumor sites. These alterations were accompanied by an increased level of IL-12 and IFN-γ, and decreased level of IL-10 and TGF-β1. Furthermore, we confirmed SLC induced the maturation of DCs via NF-κB p65 and this maturation would benefit the combination therapy.
20339029	Melanoma	Inhibit immunity	CCL21 expression by melanoma tumors in mice was associated with an immunotolerant microenvironment, which included the induction of lymphoid-like reticular stromal networks, an altered cytokine milieu, and the recruitment of regulatory leukocyte populations. In contrast, CCL21-deficient tumors induced antigen-specific immunity. We suggest that by altering the tumor microenvironment, CCL21-secreting tumors shift the host immune response from immunogenic to tolerogenic, which facilitates tumor progression.
17567706	Hepatocellular Carcinoma	Promote immunity (infiltration)	As a result, rAAV-SLC induced a significant delay of tumor progression, which was paralleled by a profound infiltration of DCs and activated CD4(+) T cells and CD8(+) T cells (CD3(+) CD69(+) cells) into the tumor site. In addition, rAAV-SLC treatment was also found to reduce tumor growth in nude mice, most likely due to inhibition of neoangiogenesis.
16112911	Melanoma	Promote immunity	Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Induction of anti-TRP2 immunity depended mainly on cell-mediated immunity, which was regulated by timing and route of CCL21 administration with DNA vaccine.

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CCL21 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CCL21 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.195	0.851
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.771	0.712
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.22	0.9
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.522	0.468
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.675	0.59
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.317	0.852
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	2.037	0.0791
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	2.529	0.143
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.57	0.39
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.529	0.408
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.1	0.428
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.811	0.058

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CCL21 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCL21. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCL21. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCL21. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCL21. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CCL21 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CCL21 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CCL21
Name	chemokine (C-C motif) ligand 21
Aliases	SLC; exodus-2; TCA4; CKb9; 6Ckine; ECL; beta chemokine exodus-2; secondary lymphoid tissue chemokine; Effici ......
Chromosomal Location	9p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CCL21 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CCL21